Zynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor Fitzgerald
A number of other equities research analysts also recently commented on ZYNE. Zacks Investment Research raised Zynerba Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 10th. ValuEngine upgraded Zynerba Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, September 1st. Oppenheimer restated a hold rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, November 14th. Roth Capital cut Zynerba Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the company from $30.00 to $7.00 in a research report on Tuesday, August 8th. Finally, CIBC restated a market perform rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, August 15th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals has an average rating of Hold and a consensus target price of $15.00.
Shares of Zynerba Pharmaceuticals (NASDAQ ZYNE) traded down $1.21 during midday trading on Monday, hitting $13.37. The company had a trading volume of 1,219,400 shares, compared to its average volume of 642,984. Zynerba Pharmaceuticals has a 52-week low of $5.42 and a 52-week high of $25.95.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.05). During the same period in the previous year, the business earned ($0.67) earnings per share. analysts anticipate that Zynerba Pharmaceuticals will post -2.49 EPS for the current year.
In related news, major shareholder Michael Rapp acquired 44,255 shares of the company’s stock in a transaction that occurred on Thursday, October 19th. The stock was purchased at an average price of $9.59 per share, for a total transaction of $424,405.45. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 9.91% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in shares of Zynerba Pharmaceuticals by 65,190.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 326,450 shares of the company’s stock valued at $5,539,000 after purchasing an additional 325,950 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Zynerba Pharmaceuticals by 230.7% in the 3rd quarter. Perceptive Advisors LLC now owns 130,700 shares of the company’s stock valued at $1,320,000 after purchasing an additional 230,700 shares in the last quarter. Citigroup Inc. lifted its stake in shares of Zynerba Pharmaceuticals by 13,501.1% in the 2nd quarter. Citigroup Inc. now owns 221,698 shares of the company’s stock valued at $3,762,000 after purchasing an additional 220,068 shares in the last quarter. RTW Investments LP acquired a new position in shares of Zynerba Pharmaceuticals in the 3rd quarter valued at about $1,672,000. Finally, State Street Corp acquired a new position in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at about $2,698,000. Institutional investors own 26.95% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor Fitzgerald” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/05/zynerba-pharmaceuticals-zyne-given-a-17-00-price-target-at-cantor-fitzgerald.html.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.